Towards Healthcare
U.S. Residual DNA Testing Market 2025 Trends and Updates

U.S. Residual DNA Testing Market Biologics & CDMOs Propel Growth with Cutting-Edge PCR Technologies

The U.S. residual DNA testing market is growing because increasing application of this testing in forensics and criminal investigations, immigration, infidelity, and paternity.

Content

  • Insight Code: 5972
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: August 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The U.S. residual DNA testing market forecast for 2025 to 2034. Learn about key trends, revenue projections, and innovations shaping the industry.

The U.S. residual DNA testing market includes five segments such as by product type, by application, by technology, by end user, and by region.

Some key players include Thermo Fisher Scientific, Charles River Laboratories, Bio-Rad Laboratories, Maravai LifeSciences, etc.

Key trends include the strong R&D Infrastructure and stringent regulatory frameworks.

Residual DNA testing is simply the term given to the practice of quantifying the amount of host cell DNA in a biological sample or product where host cell DNA does not belong.

Residual DNA may be present in very small quantities in the mRNA COVID-19 vaccines and other biotechnology products. Residual DNA is the amount of DNA remaining after processing and purification of the medicine and is present as small fragments.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.
Any Questions